CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Recursion Pharmaceuticals, Inc. - RXRX CFD

7.53
2.84%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Recursion Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 7.75
Open* 7.6
1-Year Change* 28.38%
Day's Range* 7.53 - 7.73
52 wk Range 4.54-16.75
Average Volume (10 days) 8.89M
Average Volume (3 months) 108.00M
Market Cap 2.13B
P/E Ratio -100.00K
Shares Outstanding 215.87M
Revenue 47.36M
EPS -1.48
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 16, 2024 7.53 0.00 0.00% 7.53 7.74 7.49
Apr 15, 2024 7.75 -0.61 -7.30% 8.36 8.42 7.74
Apr 12, 2024 8.38 -0.42 -4.77% 8.80 8.89 8.28
Apr 11, 2024 8.90 0.27 3.13% 8.63 8.90 8.49
Apr 10, 2024 8.53 0.00 0.00% 8.53 8.74 8.39
Apr 9, 2024 9.07 0.14 1.57% 8.93 9.19 8.92
Apr 8, 2024 8.96 0.09 1.01% 8.87 9.08 8.76
Apr 5, 2024 8.85 0.41 4.86% 8.44 8.91 8.39
Apr 4, 2024 8.69 -0.31 -3.44% 9.00 9.29 8.68
Apr 3, 2024 8.90 0.15 1.71% 8.75 9.31 8.70
Apr 2, 2024 8.72 -0.18 -2.02% 8.90 8.91 8.64
Apr 1, 2024 9.34 -0.55 -5.56% 9.89 9.92 9.30
Mar 28, 2024 9.92 -0.09 -0.90% 10.01 10.25 9.91
Mar 27, 2024 10.14 -0.15 -1.46% 10.29 10.34 10.04
Mar 26, 2024 10.29 -0.31 -2.92% 10.60 10.84 10.28
Mar 25, 2024 10.49 0.02 0.19% 10.47 10.87 10.38
Mar 22, 2024 10.44 -0.04 -0.38% 10.48 10.76 10.26
Mar 21, 2024 10.61 -0.61 -5.44% 11.22 11.41 10.23
Mar 20, 2024 11.04 0.55 5.24% 10.49 11.14 10.25
Mar 19, 2024 10.71 -0.08 -0.74% 10.79 11.14 10.43

Recursion Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Recursion Pharmaceuticals Inc Earnings Release
Q1 2024 Recursion Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

18:00

Country

US

Event

Recursion Pharmaceuticals Inc Annual Shareholders Meeting
Recursion Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, August 6, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Recursion Pharmaceuticals Inc Earnings Release
Q2 2024 Recursion Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 39.843 10.178 3.962 2.319
Revenue 39.843 10.178 3.962 2.319
Total Operating Expense 285.57 193.78 89.46 65.315
Selling/General/Admin. Expenses, Total 95.651 66.671 27.035 19.898
Research & Development 141.265 125.978 61.542 44.862
Unusual Expense (Income) 0 0.827 0.883 0.555
Operating Income -245.727 -183.602 -85.498 -62.996
Interest Income (Expense), Net Non-Operating 6.199 -2.879 -1.024 1.106
Other, Net 0.052 0.002 -0.484 0.011
Net Income Before Taxes -239.476 -186.479 -87.006 -61.879
Net Income After Taxes -239.476 -186.479 -87.006 -61.879
Net Income Before Extra. Items -239.476 -186.479 -87.006 -61.879
Net Income -239.476 -186.479 -87.006 -61.879
Income Available to Common Excl. Extra. Items -239.476 -186.479 -87.006 -61.879
Income Available to Common Incl. Extra. Items -239.476 -186.479 -87.006 -61.879
Diluted Net Income -239.476 -186.479 -87.006 -61.879
Diluted Weighted Average Shares 175.537 125.348 162.155 162.155
Diluted EPS Excluding Extraordinary Items -1.36424 -1.48769 -0.53656 -0.3816
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.36424 -1.48109 -0.53111 -0.37818
Depreciation / Amortization 0.379 0.304
Cost of Revenue, Total 48.275
Gross Profit -8.432
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 11.017 12.134 13.676 13.16 7.674
Revenue 11.017 12.134 13.676 13.16 7.674
Total Operating Expense 92.732 81.999 74.658 75.733 73.865
Selling/General/Admin. Expenses, Total 28.29 21.674 23.356 19.488 18.399
Research & Development 53.46 46.525 40.311 40.76 38.363
Depreciation / Amortization 1.6 0.152 0.151 0.076 0.076
Operating Income -81.715 -69.865 -60.982 -62.573 -66.191
Interest Income (Expense), Net Non-Operating 4.931 4.641 3.669 1.82 0.638
Net Income Before Taxes -76.726 -65.327 -57.492 -60.445 -65.56
Net Income After Taxes -76.726 -65.327 -57.492 -60.445 -65.56
Net Income Before Extra. Items -76.726 -65.327 -57.492 -60.445 -65.56
Net Income -76.726 -65.327 -57.492 -60.445 -65.56
Income Available to Common Excl. Extra. Items -76.726 -65.327 -57.492 -60.445 -65.56
Income Available to Common Incl. Extra. Items -76.726 -65.327 -57.492 -60.445 -65.56
Diluted Net Income -76.726 -65.327 -57.492 -60.445 -65.56
Diluted Weighted Average Shares 196.561 191.618 185.781 173.436 172.212
Diluted EPS Excluding Extraordinary Items -0.39034 -0.34092 -0.30946 -0.34851 -0.38069
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.39034 -0.33466 -0.30946 -0.34851 -0.36443
Unusual Expense (Income) 1.2 0 0 2.8
Other, Net 0.058 -0.103 -0.179 0.308 -0.007
Cost of Revenue, Total 9.382 12.448 10.84 15.409 14.227
Gross Profit 1.635 -0.314 2.836 -2.249 -6.553
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 569.814 534.718 266.437 76.398
Cash and Short Term Investments 549.912 516.562 262.126 69.883
Cash & Equivalents 549.912 285.116 262.126 69.883
Total Receivables, Net 2.753 9.09 0.156 0.151
Accounts Receivable - Trade, Net 0 0.034 0.156 0.151
Other Current Assets, Total 17.149 9.066 4.155 6.364
Total Assets 701.288 610.345 298.585 101.431
Property/Plant/Equipment, Total - Net 121.447 64.725 25.967 24.37
Property/Plant/Equipment, Total - Gross 151.562 83.462 35.929 30.085
Accumulated Depreciation, Total -30.115 -18.737 -9.962 -5.715
Intangibles, Net 1.306 1.385 1.689 0
Other Long Term Assets, Total 7.92 8.716 3.691 0.663
Total Current Liabilities 100.265 46.658 23.099 6.684
Accounts Payable 4.586 2.819 1.074 1.261
Accrued Expenses 38.856 33.749 10.952 5.346
Notes Payable/Short Term Debt 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.097 0.09 1.073 0.077
Other Current Liabilities, Total 56.726 10 10 0
Total Liabilities 215.482 67.407 56.562 24.587
Total Long Term Debt 0.536 0.633 11.414 12.418
Long Term Debt 0.536 0.633 11.414 12.418
Other Liabilities, Total 114.681 20.116 22.049 5.485
Total Equity 485.806 542.938 242.023 76.844
Preferred Stock - Non Redeemable, Net 0 0 448.312 201.109
Common Stock 0.002 0.002 0 0
Additional Paid-In Capital 1125.36 943.142 7.312 2.33
Retained Earnings (Accumulated Deficit) -639.556 -400.08 -213.601 -126.595
Total Liabilities & Shareholders’ Equity 701.288 610.345 298.585 101.431
Total Common Shares Outstanding 191.023 170.272 162.155 162.155
Short Term Investments 0 231.446 0
Goodwill, Net 0.801 0.801 0.801
Other Equity, Total 0 -0.126 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 410.522 431.02 492.125 569.814 481.618
Cash and Short Term Investments 387.322 405.87 473.145 549.912 454.646
Cash & Equivalents 387.322 405.87 473.145 549.912 454.646
Total Receivables, Net 3.164 3.051 2.057 2.753 11.635
Accounts Receivable - Trade, Net 0 0
Other Current Assets, Total 20.036 22.099 16.923 17.149 15.337
Total Assets 630.825 666.699 627.366 701.288 611.533
Property/Plant/Equipment, Total - Net 120.31 124.667 125.12 121.447 119.503
Property/Plant/Equipment, Total - Gross 161.157 162.267 158.754 151.562 146.555
Accumulated Depreciation, Total -40.847 -37.6 -33.634 -30.115 -27.052
Intangibles, Net 39.459 42.757 1.318 1.306 1.457
Other Long Term Assets, Total 7.784 7.739 8.002 7.92 8.154
Total Current Liabilities 94.118 113.959 92.15 100.265 83.036
Accounts Payable 4.265 2.086 4.247 4.586 3.89
Accrued Expenses 45.161 38.092 29.481 38.856 32.298
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.695 0.676 0.661 0.097 0.095
Other Current Liabilities, Total 43.997 73.105 57.761 56.726 46.753
Total Liabilities 192.858 197.736 197.191 215.482 223.499
Total Long Term Debt 1.126 1.155 1.179 0.536 0.561
Long Term Debt 1.126 1.155 1.179 0.536 0.561
Other Liabilities, Total 95.683 78.286 103.862 114.681 139.902
Total Equity 437.967 468.963 430.175 485.806 388.034
Redeemable Preferred Stock
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 1312.59 1250.57 1135.06 1125.36 970.096
Retained Earnings (Accumulated Deficit) -874.626 -781.609 -704.883 -639.556 -582.064
Total Liabilities & Shareholders’ Equity 630.825 666.699 627.366 701.288 611.533
Total Common Shares Outstanding 215.564 202.731 192.231 191.023 174.073
Short Term Investments 0 0
Other Equity, Total 0 0
Goodwill, Net 52.75 60.516 0.801 0.801 0.801
Deferred Income Tax 1.931 4.336
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -239.476 -186.479 -87.006 -61.879
Cash From Operating Activities -83.524 -158.614 -45.399 -57.042
Cash From Operating Activities 11.756 8.405 4.442 3.543
Non-Cash Items 39.275 19.766 6.331 0.886
Cash Interest Paid 0.055 0.68 0.989 0.485
Changes in Working Capital 104.921 -0.306 30.834 0.408
Cash From Investing Activities 193.249 -271.744 -8.74 -3.91
Capital Expenditures -37.059 -39.798 -5.831 -3.91
Other Investing Cash Flow Items, Total 230.308 -231.946 -2.909 0
Cash From Financing Activities 154.345 458.54 246.135 120.41
Financing Cash Flow Items 0 0 -0.275
Issuance (Retirement) of Stock, Net 154.435 471.338 239.812 119.98
Issuance (Retirement) of Debt, Net -0.09 -12.798 6.323 0.705
Net Change in Cash 263.763 28.182 191.996 59.458
Foreign Exchange Effects -0.307
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -65.327 -239.476 -181.984 -121.539 -55.979
Cash From Operating Activities -73.316 -83.524 -38.776 15.765 77.388
Cash From Operating Activities 3.728 11.756 8.542 5.553 2.767
Non-Cash Items 12.687 39.275 29.144 18.464 7.776
Cash Interest Paid 0.013 0.055 0.042 0.028 0.014
Changes in Working Capital -24.404 104.921 105.522 113.287 122.824
Cash From Investing Activities -5.34 193.249 201.228 148.244 143.304
Capital Expenditures -5.175 -37.059 -29.08 -20.817 -4.342
Cash From Financing Activities 1.922 154.345 7.089 4.752 2.084
Issuance (Retirement) of Stock, Net 1.946 154.435 7.156 4.796 2.106
Issuance (Retirement) of Debt, Net -0.024 -0.09 -0.067 -0.044 -0.022
Net Change in Cash -76.736 263.763 169.541 168.761 222.776
Other Investing Cash Flow Items, Total -0.165 230.308 230.308 169.061 147.646
Financing Cash Flow Items
Foreign Exchange Effects -0.002 -0.307

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Recursion Pharmaceuticals, Inc. Company profile

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. Its programs include REC-4881, REC-3599, REC-2282, REC-994, lead molecules for the treatment of C. difficile Colitis, lead molecules for the treatment of Neuroinflammation, lead molecules for the treatment of Batten Disease and lead molecules for the treatment of CMT2A.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Recursion Pharmaceuticals Inc revenues totaled $7.6M. Net loss totaled to $121.5M.

Industry: Bio Therapeutic Drugs

41S Rio Grande Street
SALT LAKE CITY
UTAH 84101
US

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

ETH/USD

3,115.84 Price
+1.220% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,767.40 Price
+0.220% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.51 Price
+0.920% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,099.30 Price
+1.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading